IL272449A - Adiponectin peptide deletions for the treatment of ocular disorders - Google Patents

Adiponectin peptide deletions for the treatment of ocular disorders

Info

Publication number
IL272449A
IL272449A IL272449A IL27244920A IL272449A IL 272449 A IL272449 A IL 272449A IL 272449 A IL272449 A IL 272449A IL 27244920 A IL27244920 A IL 27244920A IL 272449 A IL272449 A IL 272449A
Authority
IL
Israel
Prior art keywords
ocular disorders
treating ocular
adiponectin peptidomimetics
adiponectin
peptidomimetics
Prior art date
Application number
IL272449A
Other languages
English (en)
Hebrew (he)
Original Assignee
Allysta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allysta Pharmaceuticals Inc filed Critical Allysta Pharmaceuticals Inc
Publication of IL272449A publication Critical patent/IL272449A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
IL272449A 2015-05-01 2020-02-04 Adiponectin peptide deletions for the treatment of ocular disorders IL272449A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562156127P 2015-05-01 2015-05-01
US15/676,968 US10537608B2 (en) 2015-05-01 2017-08-14 Adiponectin peptidomimetics for treating ocular disorders
PCT/US2018/045527 WO2019036223A1 (en) 2015-05-01 2018-08-07 PEPTIDOMIMETICS OF ADIPONECTIN FOR THE TREATMENT OF OCULAR DISORDERS

Publications (1)

Publication Number Publication Date
IL272449A true IL272449A (en) 2020-03-31

Family

ID=57218292

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272449A IL272449A (en) 2015-05-01 2020-02-04 Adiponectin peptide deletions for the treatment of ocular disorders

Country Status (12)

Country Link
US (6) US10987401B2 (cg-RX-API-DMAC7.html)
EP (3) EP4014985A1 (cg-RX-API-DMAC7.html)
JP (1) JP7245649B2 (cg-RX-API-DMAC7.html)
KR (2) KR20170141692A (cg-RX-API-DMAC7.html)
CN (3) CN107530396B (cg-RX-API-DMAC7.html)
AU (3) AU2016257724B2 (cg-RX-API-DMAC7.html)
CA (3) CA2981822C (cg-RX-API-DMAC7.html)
DK (1) DK3288577T3 (cg-RX-API-DMAC7.html)
ES (1) ES2903448T3 (cg-RX-API-DMAC7.html)
IL (1) IL272449A (cg-RX-API-DMAC7.html)
SG (1) SG11202001140UA (cg-RX-API-DMAC7.html)
WO (2) WO2016179007A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2903448T3 (es) * 2015-05-01 2022-04-01 Allysta Pharmaceuticals Inc Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares
WO2018165218A1 (en) * 2017-03-09 2018-09-13 Allysta Pharmaceuticals, Inc Peptides for dry eye disease
CN107149676A (zh) * 2017-05-05 2017-09-12 杨硕 脂联素和脂联素/胰岛素混合液在改善及治疗眼表角膜上皮及神经损伤中的应用
WO2019061491A1 (en) * 2017-09-30 2019-04-04 Pro Sunfun Biotech Research And Development Co., Ltd. PEPTIDE FOR OCULAR CARE, COMPOSITION AND METHOD OF USE THEREOF
CN109912685B (zh) * 2017-12-13 2022-05-06 三凡生技研发股份有限公司 眼睛保护胜肽及其组合物及使用该胜肽的用途
US20190292223A1 (en) * 2018-03-23 2019-09-26 Arch Biosurgery, Inc. Sap and peptidomimetics for treatment of eye disease
CN113164551A (zh) * 2018-10-24 2021-07-23 雅利斯塔制药公司 脂联素肽模拟物制剂
JP7699426B2 (ja) * 2018-11-30 2025-06-27 ロート製薬株式会社 光線による障害からの細胞保護用眼科組成物
BR112022002467A2 (pt) 2019-09-18 2022-07-19 Alcon Inc Insertos oculares de hidrogel suave embalados a úmido
US11229549B2 (en) * 2019-09-18 2022-01-25 Vance M. Thompson Tear transplantation and multi-part contact lens with absorbent portion
US11213551B1 (en) 2021-04-05 2022-01-04 Korb Research, Llc. Ocular treatment compositions and methods of use thereof
WO2023069549A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023069255A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023107796A1 (en) * 2021-12-11 2023-06-15 The Regents Of The University Of California Ophthalmic formulations for macular degeneration
WO2024180472A1 (en) 2023-02-28 2024-09-06 Alcon Inc. Ocular inserts
KR102609115B1 (ko) * 2023-06-08 2023-12-05 주식회사 엔큐라젠 펩타이드를 포함하는 안구 질환의 치료용 조성물
WO2026032238A1 (en) * 2024-08-06 2026-02-12 The Chinese University Of Hong Kong Compositions and methods for treating tendon and ligament injuries utilizing biomaterials and adiponectin or its mimics
WO2026049532A1 (ko) * 2024-08-30 2026-03-05 서울과학기술대학교 산학협력단 알레르기성 결막염 치료를 위한 약학적 제제가 담지된 콘택트렌즈 및 이의 제작 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DE69936409T2 (de) 1998-04-28 2008-04-17 Laboratoires Serono S.A., Coinsins Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
JP2005535561A (ja) * 2002-01-18 2005-11-24 プロテミックス コーポレイション リミティド アディポネクチンのグリコアイソフォームとその使用
AU2006242651B2 (en) * 2005-04-29 2013-05-16 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2012142142A2 (en) 2011-04-12 2012-10-18 Temple University - Of The Commonwealth System Higher Education Adiponectin receptor agonists and methods of use
KR101438744B1 (ko) * 2012-08-02 2014-09-15 전남대학교산학협력단 아디포넥틴을 유효성분으로 포함하는 안구건조증 또는 염증성 안구표면 질환의 예방 또는 치료용 조성물
WO2014066775A1 (en) * 2012-10-26 2014-05-01 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
ES2903448T3 (es) * 2015-05-01 2022-04-01 Allysta Pharmaceuticals Inc Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares

Also Published As

Publication number Publication date
US20180078616A1 (en) 2018-03-22
HK1246178A1 (zh) 2018-09-07
JP2018514592A (ja) 2018-06-07
US10987401B2 (en) 2021-04-27
DK3288577T3 (da) 2022-01-10
AU2021203254A1 (en) 2021-06-17
US11273197B2 (en) 2022-03-15
EP4014985A1 (en) 2022-06-22
US20200085907A1 (en) 2020-03-19
CA2981822A1 (en) 2016-11-10
EP3288577B1 (en) 2021-10-27
JP7245649B2 (ja) 2023-03-24
AU2016257724A1 (en) 2017-10-12
CN111032070A (zh) 2020-04-17
KR20200039749A (ko) 2020-04-16
EP3288577A1 (en) 2018-03-07
US11464825B2 (en) 2022-10-11
EP3668530A1 (en) 2020-06-24
KR20170141692A (ko) 2017-12-26
SG11202001140UA (en) 2020-03-30
WO2016179007A1 (en) 2016-11-10
ES2903448T3 (es) 2022-04-01
CA3191203A1 (en) 2016-11-10
US20180161390A1 (en) 2018-06-14
US20210128671A1 (en) 2021-05-06
CN115919996A (zh) 2023-04-07
EP3288577A4 (en) 2018-12-26
US20220331393A1 (en) 2022-10-20
WO2019036223A1 (en) 2019-02-21
US20230074446A1 (en) 2023-03-09
EP3668530A4 (en) 2021-07-21
AU2016257724B2 (en) 2021-02-25
CA3071670A1 (en) 2019-02-21
AU2018318008A1 (en) 2020-02-06
CN107530396B (zh) 2022-08-26
CN107530396A (zh) 2018-01-02
CA2981822C (en) 2023-04-11
US10537608B2 (en) 2020-01-21

Similar Documents

Publication Publication Date Title
SG11202001140UA (en) Adiponectin peptidomimetics for treating ocular disorders
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL265497B (en) Methods for treating eye diseases
ZA201705673B (en) Methods for treating skin
PT3261640T (pt) Agonistas de 5ht para tratamento de distúrbios de epilepsia
GB2544294B (en) Goggles for snowsports
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
IL250838A0 (en) Devices for the treatment of heart failure
IL254393A0 (en) Methods for treating diseases associated with pathological changes in protein
HUE049518T2 (hu) Készítmények és eljárások a szem megbetegedéseinek kezelésére és diagnosztizálására
GB201512733D0 (en) Therapeutic agents for treating conditions associated with elevated GDF15
PT3119911T (pt) Compostos para uso no tratamento da doença de alzheimer em pacientes apoe4+/+
PL3145511T3 (pl) Kompozycja do leczenia oka
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
SMT202300229T1 (it) Composizioni per trattare condizioni oftalmiche
GB201701404D0 (en) Therapies for treating inflammatory disorders
PT3420084T (pt) Nova abordagem para tratamento de disfunções inflamatórias
HK1261774A1 (en) Methods for treating eye disorders
EP3177316A4 (en) Method for preventing or treating ocular disorders
GB201602011D0 (en) Treating skin disorders
GB201701933D0 (en) New methods for the treatment of hyperglycaemia
GB201521543D0 (en) Methods for the treatment of inflammatory disorders
GB201513993D0 (en) Methods for the treatment of inflammatory disorders
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders